<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02827552</url>
  </required_header>
  <id_info>
    <org_study_id>2015-A00975-44</org_study_id>
    <nct_id>NCT02827552</nct_id>
  </id_info>
  <brief_title>Description of Individual Radiosensitivity With Molecular Biomarkers in a Pediatric Oncology Population</brief_title>
  <acronym>ARPEGE BioM</acronym>
  <official_title>Integrative Molecular Analysis of Individual Radiosensitivity Among a Population of Pediatric Patients Treated With Radiation in Eastern France.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to explore prospectively the distribution of individual radiosensitivity in
      the pediatric population and to determine the predictive power of individual radiosensitivity
      biomarkers from an immunofluorescence technique on primary dermal fibroblasts
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      900 children and adolescents benefit from radiation each year in France. The mean age at
      diagnosis is 5 years; life expectancy for the 80% of them who could cure is long, and the
      incidence of radiation-related acute and mainly late complications - not evaluated to date -
      could exceed that of adults. Dysfunction of irradiated organs and growth disorders are
      specific to the pediatric subpopulation. Individual radiosensitivity of children and
      adolescents is unknown at this time, probably with large variability depending on the age
      when considering the changes in metabolic functions throughout growth. These complications
      are largely attributable to inter individual constitutional variations of cellular response
      to DNA damage.

      Subject to radiation-induced DNA damages such as double-strand breaks (DSB), cells reacts by
      triggering a whole series of phosphorylation events coordinated within multi protein
      complexes whose interplay is still misknown (DNA damage response i.e. DDR). Indirect
      Immunofluorescence cell scanning has revolutionized radiation biology research by permitting
      the detection of individual DSB in each cell nucleus in a dose range from 1 mGy to 10 Gy.
      This technique has notably confirmed that yield of unrepaired DSB is correlated with cell RS.
      From a broad spectrum of human radiosensitive skin fibroblast cell lines, the Inserm CRU 1052
      team proposed a general model of DSB signaling and repair and a molecular assay to stratify
      patients according to their individual RS.

      ARPEGE biomarqueurs is a prospective multicenter study to prospectively evaluate with this
      assay the RS of children and adolescents treated over a year in all pediatric oncology
      departments of the Region Grand Est and set thresholds in this population. 150 children are
      thus potentially includable in different centers. The assay will be performed on primary
      fibroblasts cultured from a skin biopsy taken at diagnosis. The RS of patients will be
      measured in blind. Confusion factors such as irradiated volume, skin phototype, previous
      chemotherapy regimen, smoking, comorbities (diabetes, immunodeficiency, chronic inflammatory
      disease ...) will be reported. In parallel the RT-acute toxicity will be reported according
      to NCI-CTCAE v4.0 reference scale three months of the completion of RT then periodically
      during 15 years.

      Screening hypersensitive patients would be a major step forward in the management of cancers,
      opening a view to personalized medicine.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2017</start_date>
  <completion_date type="Anticipated">March 2033</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>skin fibroblast radiosenstivity</measure>
    <time_frame>up to 5 months</time_frame>
    <description>residual double-strand breaks 24h after ex vivo radiation assessed with indirect immunofluorescence (gammaH2AX marker).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>early cutaneous, mucosal and hematological early radiation toxicity</measure>
    <time_frame>3 months</time_frame>
    <description>early radiation toxicity pattern assessed according to CTACAE v4.0 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pATM nucleoshuttling</measure>
    <time_frame>up to 5 months</time_frame>
    <description>pATM foci counted 10 minutes and 1 hour after ex vivo radiation assessed with indirect immunofluorescence (pATM marker).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean micronuclei number</measure>
    <time_frame>up to 5 months</time_frame>
    <description>micronuclei counted 24 hours after ex vivo radiation assessed with indirect immunofluorescence (DAPI marker).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late radiation toxicity</measure>
    <time_frame>15 years</time_frame>
    <description>deterministic tissue effects as well as secondary malignancies occurring in radiation field more than 3 months and up to 15 years after RT, using CTCAE v4.0 scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">222</enrollment>
  <condition>Cancer-related Problem/Condition</condition>
  <arm_group>
    <arm_group_label>ARPEGE BioM</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>N/A (not a randomized study)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>skin biopsy</intervention_name>
    <description>skin biopsy performed prior radiation to characterize in blind the individual radiosensitivity of the patient</description>
    <arm_group_label>ARPEGE BioM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children &lt; 18 years old

          -  Patient with an indication of radiotherapy

          -  Patient must be affiliated to a social security system

          -  Patient under parental autority

          -  Ability to provide an informed written consent form

        Exclusion Criteria:

          -  Contraindications for skin biopsy

          -  Contraindications for radiotherapy

          -  Referred to palliative radiotherapy

          -  Prior radiotherapy in the same area

          -  Indication of hypofractionated radiotherapy

          -  Patient monitoring impossible

          -  Patients deprived of liberty or under supervision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>VOGIN GUILLAUME, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>BERNIER CHASTAGNER VALERIE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MERLIN JEAN LOUIS, PR</last_name>
    <phone>+ 33 3 83 59 83 07</phone>
    <email>jl.merlin@nancy.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>FERNANDES LAURINDA</last_name>
    <phone>+ 33 3 83 59 84 87</phone>
    <email>l.fernandes@nancy.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25 000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LAITHIER Véronique, MD</last_name>
      <email>vlaithier@chu-besancon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21 000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BRIANDET Claire, MD</last_name>
      <email>claire.briandet@chu-dijon.fr</email>
    </contact>
    <contact_backup>
      <last_name>BOTTOLLIER LEMALLAZ Elodie, MD</last_name>
      <email>elodie.bottollier-lemallaz@chu-dijon.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Georges-François-Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21 000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TRUC Gilles, MD</last_name>
      <email>gtruc@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69 000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>CARRIE Christian, MD</last_name>
      <email>christian.carrie@lyon.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>CLAUDE Line, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69 000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BERGERON Christophe, MD</last_name>
      <email>christophe.bergeron@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51 100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PLUCHART Claire, MD</last_name>
      <email>cpluchart@chu-reims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67 065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VIGNERON Céline, MD</last_name>
      <email>cvigneron@strasbourg.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67 098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ENTZ-WERLE Natacha, MD</last_name>
      <email>natacha.entz-werle@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GAMBART Marion, MD</last_name>
      <email>gambart.m@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IUCT Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LAPRIE Anne, MD</last_name>
      <email>Laprie.Anne@iuct-oncopole.fr</email>
    </contact>
    <contact_backup>
      <last_name>DUCASSOU Anne, M/D</last_name>
      <email>Ducassou.Anne@iuct-oncopole.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-lès-Nancy</city>
        <zip>54 500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VOGIN Guillaume, MD</last_name>
      <email>g.vogin@nancy.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>BERNIER CHASTAGNER Valérie, MD</last_name>
      <email>v.bernier@nancy.unicancer.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Vandoeuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CHASTAGNER Pascal, MD</last_name>
      <email>p.chastagner@chru-nancy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2016</study_first_submitted>
  <study_first_submitted_qc>July 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pediatric oncology</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>radiosensitivity</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

